

Evidence-Based Lung Cancer Treatment Algorithmic Tests

- I. Lung cancer treatment algorithmic tests with sufficient evidence of clinical validity and utility are considered **medically necessary** when:
 - A. The member has a non-squamous non-small cell lung cancer (NSCLC), **AND**
 - B. The member's tumor size is less than 5 cm, **AND**
 - C. The member has no positive lymph nodes (stages I and IIa), **AND**
 - D. The member is considering adjuvant platinum-containing chemotherapy.
- II. Lung cancer treatment algorithmic tests with sufficient evidence of clinical validity and utility are considered **investigational** for all other indications where clinical validity and utility have not been demonstrated.

DEFINITIONS

1. **Adjuvant** therapy is a medication (such as chemotherapy or endocrine therapy) given after the surgical removal of a cancerous tumor.

REFERENCES

1. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MoIDX: Predictive Classifiers for Early Stage

Non-Small Cell Lung Cancer (L38238). Available at:

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38238>

2. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Billing and Coding. MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A58031). Available at:
<https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58031>